NWBO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 22:59):

Stats
Dzisiejszy wolumen	1.33M
Średni wolumen	1.73M
Kapitalizacja rynkowa	562.62M
EPS	$0 ( 2024-02-29 )
Następna data zysków	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.88
ATR14	$0.00300 (0.63%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-16	Malik Navid	Buy	125 000	Common Stock
2023-11-17	Malik Navid	Buy	150 000	Common Stock
2023-11-17	Malik Navid	Buy	295 000	Common Stock
2023-04-03	Bosch Marnix L	Buy	119 355	Common Stock
2023-04-04	Boynton Alton L	Sell	6 794 191	STOCK OPTIONS

INSIDER POWER
-81.43
Last 96 transactions
Buy: 331 589 317 \| Sell: 61 146 214

Wolumen Korelacja

Długi: 0.00 (neutral)

Krótki: 0.09 (neutral)

Signal:(53.692) Neutral

Northwest Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Northwest Korelacja - Waluta/Towar

0.44
( neutral )

0.49
( neutral )

0.00
( neutral )

-0.51
( weak negative )

Northwest Finanse

Annual	2023
Przychody:	$1.93M
Zysk brutto:	$199 000 (10.30 %)
EPS:	$-0.0559

FY	2023
Przychody:	$1.93M
Zysk brutto:	$199 000 (10.30 %)
EPS:	$-0.0559

FY	2022
Przychody:	$1.68M
Zysk brutto:	$135 000 (8.02 %)
EPS:	$-0.130

FY	2021
Przychody:	$1.01M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$0.210

Financial Reports:

No articles found.

Northwest

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.